Chronic Pruritus in the Geriatric Population

Taige Cao, Hong Liang Tey, Gil Yosipovitch

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Topical treatments are generally safe. Systemic treatments are chosen depending on the condition, comorbid diseases, and drug interactions. Treatment options are limited. Progress has been made in identifying itch-selective mediators over the last decade. Numerous new medications are currently undergoing clinical trials and they are anticipated to enter the clinics in the near future.

Original languageEnglish (US)
Pages (from-to)199-211
Number of pages13
JournalDermatologic Clinics
Volume36
Issue number3
DOIs
StatePublished - Jul 1 2018

Fingerprint

Pruritus
Geriatrics
Drug Interactions
Causality
Nervous System
Population
Immune System
Clinical Trials
Delivery of Health Care

Keywords

  • Classification
  • Diagnosis
  • Geriatrics
  • Pruritus
  • Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Chronic Pruritus in the Geriatric Population. / Cao, Taige; Tey, Hong Liang; Yosipovitch, Gil.

In: Dermatologic Clinics, Vol. 36, No. 3, 01.07.2018, p. 199-211.

Research output: Contribution to journalReview article

Cao, Taige ; Tey, Hong Liang ; Yosipovitch, Gil. / Chronic Pruritus in the Geriatric Population. In: Dermatologic Clinics. 2018 ; Vol. 36, No. 3. pp. 199-211.
@article{b55d3534838c4b4cae84f95de7c8fa75,
title = "Chronic Pruritus in the Geriatric Population",
abstract = "Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Topical treatments are generally safe. Systemic treatments are chosen depending on the condition, comorbid diseases, and drug interactions. Treatment options are limited. Progress has been made in identifying itch-selective mediators over the last decade. Numerous new medications are currently undergoing clinical trials and they are anticipated to enter the clinics in the near future.",
keywords = "Classification, Diagnosis, Geriatrics, Pruritus, Therapeutics",
author = "Taige Cao and Tey, {Hong Liang} and Gil Yosipovitch",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.det.2018.02.004",
language = "English (US)",
volume = "36",
pages = "199--211",
journal = "Dermatologic Clinics",
issn = "0733-8635",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Chronic Pruritus in the Geriatric Population

AU - Cao, Taige

AU - Tey, Hong Liang

AU - Yosipovitch, Gil

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Topical treatments are generally safe. Systemic treatments are chosen depending on the condition, comorbid diseases, and drug interactions. Treatment options are limited. Progress has been made in identifying itch-selective mediators over the last decade. Numerous new medications are currently undergoing clinical trials and they are anticipated to enter the clinics in the near future.

AB - Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Topical treatments are generally safe. Systemic treatments are chosen depending on the condition, comorbid diseases, and drug interactions. Treatment options are limited. Progress has been made in identifying itch-selective mediators over the last decade. Numerous new medications are currently undergoing clinical trials and they are anticipated to enter the clinics in the near future.

KW - Classification

KW - Diagnosis

KW - Geriatrics

KW - Pruritus

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85044101231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044101231&partnerID=8YFLogxK

U2 - 10.1016/j.det.2018.02.004

DO - 10.1016/j.det.2018.02.004

M3 - Review article

VL - 36

SP - 199

EP - 211

JO - Dermatologic Clinics

JF - Dermatologic Clinics

SN - 0733-8635

IS - 3

ER -